Answers are grounded in this paper and cite their sources.
Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive). In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.
No takes yet. Share an insight, caveat, or question.
International Breast Cancer Study Group (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: